Glycaemic control and hypoglycaemia in metformin-treated T2DM patients with exenatide BID vs insulin lispro TID added to titrated insulin glargine QD: the 4B trial

被引：0
|
作者：
Wolffenbuttel, B. H. R. [1 ]
Nauck, M. A. [2 ]
Shaginian, R.
Malone, J. [3 ]
Cleall, S. [4 ]
de Vries, D.
Hoogwerf, B.
MacConell, L. [5 ]
Diamant, M. [6 ]
机构：
[1] Univ Groningen, NL-9700 AB Groningen, Netherlands
[2] Diabet Zentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Windlesham, Surrey, England
[5] Bristol Myers Squibb Co, San Diego, CA USA
[6] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 41 条
  • [21] Glycaemia optimization treatment (GOT): Glycaemic control and rate of severe hypoglycaemia for 5 different dosing algorithms of insulin glargine (GLAR) in patients with type 2 diabetes mellitus (T2DM)
    Tanenberg, R. J.
    Zisman, A.
    Stewart, J. A.
    [J]. DIABETOLOGIA, 2006, 49 : 601 - 602
  • [22] Exenatide added to insulin glargine-treated patients with type 2 diabetes provided excellent fasting and postprandial control with weight loss and no increased risk of hypoglycaemia
    Bergenstal, R. M.
    Buse, J. B.
    Glass, L. C.
    Heilmann, C. R.
    Lewis, M. S.
    Kwan, A. Y. M.
    Hoogwerf, B. J.
    Rosenstock, J.
    [J]. DIABETOLOGIA, 2010, 53 : S37 - S37
  • [23] Harmony 4: 3-Year Efficacy of Albiglutide (Albi) vs. Insulin Glargine (Glar) in Patients with T2DM
    Weissman, Peter
    Stewart, Murray
    Cirkel, Deborah
    Ye, June
    Ambery, Philip
    [J]. DIABETES, 2014, 63 : A246 - A246
  • [24] Glycaemic control and safety of insulin glargine (GLAR) in elderly patients with type 2 diabetes mellitus (T2DM): The GOAL A1C study
    Halter, J.
    Kennedy, L.
    Miller, M.
    Herman, W.
    [J]. DIABETOLOGIA, 2006, 49 : 602 - 603
  • [25] Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes The SURPASS-5 Randomized Clinical Trial
    Dahl, Dominik
    Onishi, Yukiko
    Norwood, Paul
    Huh, Ruth
    Bray, Ross
    Patel, Hiren
    Rodriguez, Angel
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (06): : 534 - 545
  • [26] Improved Glucose Control without Increased Hypoglycemia Risk at Any Level of HbA1c Reduction with Insulin Glargine/Lixisenatide Fixed-Ratio Combination (LixiLan) vs. Insulin Glargine Alone Both Added On to Metformin in Type 2 Diabetes (T2DM)
    Rosenstock, Julio
    Guerci, Bruno
    Paranjape, Sachin
    Berria, Rachele
    Souhami, Elisabeth
    Aroda, Vanita
    [J]. DIABETES, 2015, 64 : A44 - A45
  • [27] Comparison of Insulin Glargine vs. NPH Insulin in Basal-Bolus Therapies in T2DM Patients and CKD: Preliminary Results of a Prospective, Randomized, Open-Label Trial
    Rocha Betonico, Carolina Castro
    De Oliveira Titan, Silvia Maria
    Correa-Giannella, Maria Lucia
    Nery, Marcia
    Queiroz, Marcia Silva
    [J]. DIABETES, 2016, 65 : A144 - A145
  • [28] Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS
    Andrea Giaccari
    R. C. Bonadonna
    R. Buzzetti
    G. Perseghin
    D. Cucinotta
    C. Fanelli
    A. Avogaro
    G. Aimaretti
    M. Larosa
    V. Pagano
    G. B. Bolli
    [J]. Acta Diabetologica, 2021, 58 : 789 - 796
  • [29] Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS
    Giaccari, Andrea
    Bonadonna, R. C.
    Buzzetti, R.
    Perseghin, G.
    Cucinotta, D.
    Fanelli, C.
    Avogaro, A.
    Aimaretti, G.
    Larosa, M.
    Pagano, V
    Bolli, G. B.
    [J]. ACTA DIABETOLOGICA, 2021, 58 (06) : 789 - 796
  • [30] Triple therapy in type 2 diabetes (T2DM): Benefits of insulin glargine (GLAR) over rosiglitazone (RSG) added to combination therapy of sulfonylurea plus metformin (SU plus MET) in insulin-naive patients
    Rosenstock, J
    Sugimoto, D
    Strange, P
    Stewart, J
    Soltes-Rak, E
    Dailey, G
    [J]. DIABETES, 2004, 53 : A145 - A145
12345